|
|
|
Volumn 344, Issue , 2012, Pages
|
|
Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
RANIBIZUMAB;
COST BENEFIT ANALYSIS;
DRUG COST;
ECONOMICS;
HUMAN;
NATIONAL HEALTH SERVICE;
NOTE;
RETINA MACULA DEGENERATION;
UNITED KINGDOM;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
GREAT BRITAIN;
HUMANS;
MACULAR DEGENERATION;
STATE MEDICINE;
|
|
EID: 84873032018
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
